Last checked at 7 Mar 2024 09:38
GSK observes positive data in Blenrep trial for blood cancer treatment
(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,778.00
Bid:
1,774.00
Ask:
1,774.50
Change:
0.00 (0.00%)
Spread:
0.50 (0.028%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
1,778.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.FTSE 100 movers: Lloyds takes top spot after strong Q1, TSB float
Thu, 01st May 2014 14:32
Domestic lender Lloyds rose into the top spot after saying that underlying profits rose by over a fifth in the first quarter and it continues to expect to apply to regulators in the second half to restart dividend payments. That came as it announced TSB bank is due to float in London before the end of June, selling at least a 25 per cent stake of the recovering business. Most of Lloyds's key financial metrics continued to 'appreciate measurably' in the first quarter, according to Hargreaves Lansdown Stockbrokers. "Lloyds is often seen as a proxy for the UK economy, and although they are inextricably linked, both are beginning to prosper after a long period of austerity," said Head of Equities Richard Hunter.Profits at oil and gas company BG Group rose as it regained losses incurred earlier in the week, which came on the back of lower production volumes and higher costs, as well as the surprise exit of its Chief Executive.Earnings fell 2.4% at BSkyB in the third quarter despite a rise in revenues, but continued investment in connected television services was repaid with better-than-expected new subscriptions, pushing shares higher throughout today's session.Communications services giant WPP was higher after announcing it has acquired Canadian creative digital marketing agency Twist Image Multimedia. Drugs giant GlaxoSmithKline rose after it announced that the US Food and Drug Administration (FDA) has approved its Incruse medication, Ellipta.Meanwhile, Sainsbury, Tesco and Morrison were all notable fallers this afternoon after the latter unveiled plans to slash the price of 1,2000 products by as much as 60% in an effort to take a greater slice of the market share. As many as 40% of the products will be own-brand items. Broker Bernstein said the size of the move marked "a big departure" and said the company was "dropping the ultimate bomb". Scottish engineering group Weir declined after Numis Securities downgraded its rating for the stock from 'add' to 'hold', saying that it sees little upside after the stock's recent strong run. That came after the group posted in line trading in the last four months.Engine maker Rolls-Royce fell into the red after saying that full-year revenues and profits are likely to be hit by foreign exchange headwinds with underlying results flat.FTSE 100 - RisersLloyds Banking Group (LLOY) 79.00p +4.83%Hargreaves Lansdown (HL.) 1,218.00p +4.10%BG Group (BG.) 1,235.50p +3.13%Aggreko (AGK) 1,623.00p +2.92%Royal Bank of Scotland Group (RBS) 306.90p +2.71%British Sky Broadcasting Group (BSY) 900.50p +2.33%Johnson Matthey (JMAT) 3,342.00p +2.11%Reckitt Benckiser Group (RB.) 4,868.00p +1.95%International Consolidated Airlines Group SA (CDI) (IAG) 411.90p +1.93%Royal Mail (RMG) 539.50p +1.89%FTSE 100 - FallersSainsbury (J) (SBRY) 323.10p -3.75%Weir Group (WEIR) 2,603.00p -3.23%Tesco (TSCO) 284.45p -2.90%Vodafone Group (VOD) 218.45p -2.46%Antofagasta (ANTO) 770.00p -2.16%Randgold Resources Ltd. (RRS) 4,690.00p -1.88%Rolls-Royce Holdings (RR.) 1,031.00p -1.81%Morrison (Wm) Supermarkets (MRW) 197.90p -1.49%Fresnillo (FRES) 839.00p -1.47%Anglo American (AAL) 1,561.50p -1.30%NR
More News
7 Mar 2024 07:21
GSK reports more encouraging trial results for Blenrep
(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.
Read more5 Mar 2024 11:03
GSK says ViiV's cabotegravir study supports longer HIV dose interval
(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.
Read more5 Mar 2024 07:26
GSK's ViiV upbeat on ultra-long-acting HIV treatment study
(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).
Read more29 Feb 2024 09:44
TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement
(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.
Read more29 Feb 2024 07:22
GSK reaches settlement in another Zantac case
(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.
Read more26 Feb 2024 08:25
GSK gonorrhoea treatment achieves efficacy endpoint in latest trial
(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.
Read more26 Feb 2024 07:22
GSK reports positive results from gonorrhoea treatment trial
(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.
Read more21 Feb 2024 09:47
GSK reports encouraging results for ViiV's Cabenuva HIV treatment
(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.
Read more21 Feb 2024 07:22
GSK's ViiV sees success in latest HIV treatment trial
(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.
Read more20 Feb 2024 15:10
PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky
(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.
Read more20 Feb 2024 08:55
IN BRIEF: Diageo welcomes GSK's CFO as non-executive director
Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."
Read more15 Feb 2024 14:44
UK dividends calendar - next 7 days
| Friday 16 February | |
| JPMorgan Asia Growth & Income PLC | dividend payment date |
| JPMorgan Japan Small Cap Growth & Income PLC | dividend payment date |
| Murray International Trust PLC | dividend payment date |
| Premier Miton Group PLC | dividend payment date |
| Schroder Oriental Income Fund | dividend payment date |
| Solid State PLC | dividend payment date |
| Monday 19 February | |
| no events scheduled | |
| Tuesday 20 February | |
| Invesco Bond Income Plus Ltd | |
| Wednesday 21 February | |
| no events scheduled | |
| Thursday 22 February | |
| abrdn Asia Focus PLC | ex-dividend payment date |
| Alumasc Group PLC | ex-dividend payment date |
| AstraZeneca PLC | ex-dividend payment date |
| BlackRock Throgmorton Trust PLC | ex-dividend payment date |
| Braemar PLC | ex-dividend payment date |
| easyJet PLC | ex-dividend payment date |
| Ecofin US Renewables Infrastructure Trust PLC | ex-dividend payment date |
| Endeavour Mining PLC | ex-dividend payment date |
| FRP Advisory Group PLC | ex-dividend payment date |
| Gateley Holdings PLC | ex-dividend payment date |
| GSK PLC | ex-dividend payment date |
| Hercules Site Services PLC | ex-dividend payment date |
| Jersey Electricity PLC | ex-dividend payment date |
| Land Securities Group PLC | ex-dividend payment date |
| Molten Ventures VCT PLC | ex-dividend payment date |
| Northern Bear PLC | ex-dividend payment date |
| Redrow PLC | ex-dividend payment date |
| Samuel Heath & Sons PLC | ex-dividend payment date |
| Titon Holdings PLC | ex-dividend payment date |
| Unilever PLC | ex-dividend payment date |
| Van Elle Holdings PLC | ex-dividend payment date |
| Virgin Money UK PLC | ex-dividend payment date |
| Witan Investment Trust PLC | ex-dividend payment date |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
15 Feb 2024 11:02
Berenberg hikes target price on GSK
(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.
Read more15 Feb 2024 09:45
LONDON BROKER RATINGS: Jefferies cuts Kingfisher but Citi raises
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:
Read more